23% y-o-y ARR growth in Q1, adj. EBITDA of DKK -3.7m "One-off" headwinds in Q1 means unchanged FY'24...
Cell impact visade som väntat fortsatt en rörelseförlust under kvartalet och negativa kassaflöden.
Redeye saw a sales development that was stronger than expected.
Ökat fokus på nya projekt Carlsquare Equity Research ser den nya influensasatsningen som en lovande ...
Redeye comments on Northbaze Q1 2024 report. EBITDA margin was good.
NoHo Partners hosted a CMD yesterday, where it talked about its new strategy and long-term targets f...
Redeye comments on Embracer’s Q4-report which saw lower topline than expected while adjusted EBIT wa...
Kapsaicinproducenten XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) genomgick ...
Positive growth outlook for margin-accretive Water segment.
Redeye notes that Neonode's strategic shift has resulted in a first license agreement for it's touch...
Expect continued M&A, mainly in Germany 6% adj. EBITA CAGR '23-'26e, M&A to support 10% growth 12-9x...
Redeye leaves its comments on today's press release from Xbrane confirming the succesful scale up of...
Redeye notes that a new German clinical study has been published, presenting the improvement the Nev...
Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduc...
Redeye comments on the critical financial situation of Amniotics and the rejection of the acquisitio...
Organic sales decline of 11% y-o-y EBIT margin of 8.
Redeye retains its positive view of Vertiseit following a directed share issue.
Alisa Bank completed the combination with PURO Finance and issued a guidance for 2024.
Late last night, NoHo Partners updated its financial targets for the strategy period 2025-2027.
Redeye provides a short research note following Scandinavian ChemoTech's anouncement of its first or...